홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Etodolac

HCID 3308
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
41340-25-4
표준 SMILES
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
InChIKey
NNYBQONXHNTVIJ-UHFFFAOYSA-N
분자식
C17H21NO3
평균 분자량
287.35 g/mol
단동위원소 질량
287.15214353

개요

Etodolac can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.

이름 및 식별자

우선 이름
Etodolac
IUPAC
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
영어명
Etodolac
분자식
C17H21NO3
분자량
287.35

이름 및 동의어

etodolac41340-25-4Etodolic acidLodineUltradolLodine XLEdolanRamodarEtodolacoZedolacAY-24236Etodolacum
이름 더 보기
HypenEtopenRAK-591OstelucEtodineay24236
FlancoxTedolanAY 24236AY-24,236EccoxolacNapilacLodin xl1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid

데이터베이스 식별자

CAS
41340-25-4
PubChem CID
3308
DTXSID
DTXSID9020615
ChEMBL
CHEMBL622
ChEBI
CHEBI:4909
UNII
2M36281008
EC Number
629-689-1
Nikkaji
J16.541G

물성

구조 계산 물성

XLogP
2.8
극성 표면적
62.3 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
3
회전 가능 결합 수
4
무거운 원자 수
21
형식 전하
0
복잡도
399

실험 및 물리화학적 성질

Drugs · 3건

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP · 2건

2.5

2.75

Solubility3.92e-02 g/L
Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Animal DrugsActive Ingredients (Etodolac) -> FDA Greenbook
Melting Point145 - 148 °C
Physical DescriptionSolid
Dissociation Constants4.65
Collision Cross Section · 2건

164.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

163.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P318, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 50 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

Hazard Traits - Developmental Toxicity; Reproductive Toxicity

Etodolac: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (100%)

독성 정보

Hepatotoxicity · 1건

Prospective studies show that 1% to 2% of patients taking etodolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (greater than 3 fold elevated) occur in less than 1% of patients.

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Etodolac

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2건

◉ Summary of Use during Lactation

◈ What is etodolac?

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding> 99% bound, primarily to albumin
Pharmacodynamics · 1건

Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion _in vivo_.

Mechanism of Action · 1건

Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

Biological Half-LifeTerminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours
Metabolism/Metabolites · 2건

Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.

Etodolac has known human metabolites that include (2S,3S,4S,5R)-6-[2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.

관련 반응

14건
반응 기록 만들기
HRID 98464 반응식
HRID 98464반응물로
HRID 268678 반응식
HRID 268678반응물로
HRID 268680 반응식
HRID 268680반응물로
HRID 834395 반응식
HRID 834395생성물로반응물로
HRID 838763 반응식
HRID 838763반응물로
HRID 901055 반응식
HRID 901055반응물로
HRID 945126 반응식
HRID 945126생성물로반응물로
HRID 946786 반응식
HRID 946786생성물로반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

물리화학적 성질

녹는점
145 · 145-1480C
끓는 점
507.9 · 507.9±45.0 °C(Predicted)
밀도
1.193 · 1.193±0.06 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도
물에는 거의 녹지 않으며, 아세톤과 에탄올에는 잘 녹습니다(96%).
물리적 상태
Solid
산도 계수 (pKa)
4.65 · 4.65(at 25℃)
색상
White to Orange to Green
수용성
40 mg/L · 40mg/L(37℃)
Merck
14 · 14,3874
BCS Class
2 · 2
주요 응용
의약품(소분자)
InChI
1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
InChIKey
NNYBQONXHNTVIJ-QGZVFWFLSA-N
SMILES
CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12
EPA
3 · Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (41340-25-4)

화학적 성질

Crystalline Solid

안전 데이터

wgk
3
rtecs
UQ0360000
ridadr
3249
HS 번호
2934999090
risk_code
23/24/25-40-36-25-36/37/38
hazard_code
T,Xi
safety_code
22-36-45-26-36/37
포장분류
III
위험 등급
6.1(b)
Hazard Classifications
Acute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
FDA Pharmacological Classification · 6건

2M36281008

ETODOLAC

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Etodolac is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of etodolac is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2건

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Absorption, Distribution and Excretion · 4건

Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.

It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.

390 mL/kg

Oral cl=49.1 mL/h/kg [Normal healthy adults]

Cellular LocationsCytoplasm
Metabolite PathwaysEtodolac Action Pathway

용도 및 제조

UsesUse (kg) in USA (2002): 25800
Use Classification · 2건

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals

응용 분야 · 3건

개요Etodolac (etodolic acid) is a non-steroidal antiinflammatory/analgesic agent useful in the treatment of various inflammatory conditions, including rheumatoid and osteoarthritis.

용도Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Etodolac displays anti-inflammatory effects in both adjuvant arthritic and normal rats. E todolac is an anti-inflammatory; analgesic.

일반 설명Etodolac (Lodine, Ultradol), a chiral, COX-2 selectiveNSAID drug that is marketed as a racemate, possesses an indolering as the aryl portion of this group of NSAID drugs.It shares many similar properties of this group and is indicatedfor short- and long-term management of pain and OA.Similar to ketorolac, etodolac exhibits several uniqueenantioselective pharmacokinetic properties. For example,the “inactive” (R)-enantiomer has approximately a 10-foldhigher plasma concentration than the active (S)-enantiomer.Furthermore, the active (S)-enantiomer is less protein boundthan its (R)-enantiomer and therefore has a very large volumeof distribution. It is well absorbed with an elimination halflifeof 6 to 8 hours. Etodolac is extensively metabolized intothree major inactive metabolites, 6-hydroxy etodolac (via aromatichydroxylation), 7-hydroxy-etodolac (via aromatic hydroxylation),and 8-(1'-hydroxylethyl) etodolac (via benzylichydroxylation), which are eliminated as the correspondingether glucuronides. Its unstable, acyl glucuronide, however,is subject to enterohepatic circulation and reactivation tothe parent drug, similar to other NSAIDS in this class.

상·하류 제품 정보

상류 원료

포수클로랄Ethyl propionylacetate에틸아닐린(2-)수소화 리튬알미늄염화옥살릴인돌7-Ethyl tryptophol라크593S-에토돌락케토(3-)-노르말발레리산메틸에스테르
추가 설명 · 1건

정의ChEBI: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.